Home/ Stocks/ NRXP

NRX Pharmaceuticals, Inc. Common Stock

NRXP XNAS

$2.13 +0.31 (+17.51%) ▲ 15-min delayed

Open

$1.89

High

$2.14

Low

$1.82

Volume

1.57M

Market Cap

$56.41M

About NRX Pharmaceuticals, Inc. Common Stock

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Sector: PHARMACEUTICAL PREPARATIONS Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$242.0K	$-5,890,000	$-0.27
Q2 2025	$0	$-17,581,000	$-0.98
Q1 2025	$0	$-5,512,000	$-0.36
FY 2024	$0	$-25,126,000	$-2.36

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for NRXP yet. Check out our latest market news or earnings calendar.

Get NRXP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on NRX Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.